Results 81 to 90 of about 2,105 (152)

Enfortumab Vedotin-Related Skin Toxicities: Insights From Clinical and Histopathological Analysis. [PDF]

J Dermatol
Kuma Y, Kido-Nakahara M, Kuba-Fuyuno Y, Matsumoto T, Oda Y, Eto M, Nakahara T.   +6 more
europepmc   +1 more source

Outcomes of Enfortumab Vedotin Treatment in Patients Ineligible for the EV-301 Trial. [PDF]

In Vivo
Nakamura K, Kobari Y, Ishiyama Y, Kondo H, Inakawa T, Nemoto Y, Fukuda H, Yoshida K, Iizuka J, Shimmura H, Kobayashi H, Hashimoto Y, Ishida H, Kondo T, Takagi T.   +14 more
europepmc   +1 more source

Long-Term Control after Intermittent Reintroduction of Enfortumab Vedotin in Metastatic Urothelial Carcinoma: A Case Report. [PDF]

Case Rep Oncol
Fujii K, Shirotake S, Yamamura S, Igarashi D, Takahashi T, Umezawa Y, Takamatsu K, Hagiwara M, Kaneko G, Oyama M.   +9 more
europepmc   +1 more source

Correction to: Astellas article: UK multidisciplinary recommendations on use of combination first-line enfortumab vedotin▼ and pembrolizumab in advanced urothelial carcinoma. [PDF]

Oncologist
europepmc   +1 more source

Multiple Bone Metastases From Non-Muscle Invasive Bladder Cancer Responding to Combination Therapy With Enfortumab Vedotin and Pembrolizumab: A Case Report. [PDF]

IJU Case Rep
Kanemoto S, Yamamoto S, Hino K, Tsuboi K, Kakizaki M, Nishiyama Y, Fukata S, Arata R, Inoue K, Ono N.   +9 more
europepmc   +1 more source

Outcomes and Management of Dermatologic Toxicity Following Enfortumab Vedotin Rechallenge in Patients With Metastatic Urothelial Carcinoma: A Retrospective Single-Center Study. [PDF]

Cancer Rep (Hoboken)
Kawahara T, Nagumo Y, Yamaguchi A, Hamada K, Tanuma K, Nitta S, Shiga M, Ikeda A, Kandori S, Hoshi A, Nishiyama H.   +10 more
europepmc   +1 more source

Cost-effectiveness analysis of enfortumab vedotin and pembrolizumab versus chemotherapy for patients with untreated advanced urothelial cancer in the United Kingdom. [PDF]

BMJ Open
Wu Q, Li Q, Qin Y.
europepmc   +1 more source

First-line enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma-commentary on patient-reported outcomes in EV-302. [PDF]

Transl Androl Urol
Liedberg F, Ståhl O, Bobjer J.
europepmc   +1 more source

Pan-Asian subgroup analysis of EV-302/KEYNOTE-A39: a phase 3 study to evaluate enfortumab vedotin and pembrolizumab in patients with untreated advanced urothelial carcinoma. [PDF]

Int J Clin Oncol
Kikuchi E, Van der Heijden MS, Valderrama BP, Gupta S, Bedke J, Shin SJ, Li JR, Guo J, Danchaivijitr P, Kanesvaran R, Park SH, Su WP, Kandori S, Bae WK, Wong A, Gorla S, Bavle A, Yu X, Lu YT, Powles T.   +19 more
europepmc   +1 more source

Neoadjuvant Therapy in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer: Recent Progress, Challenges, and Future Directions in the Era of TAR-200 and Enfortumab Vedotin Plus Pembrolizumab. [PDF]

Oncol Ther
Di Lorenzo G, Di Maio M, Buonerba C.
europepmc   +1 more source